Background and objectives Hyperuricemia is an independent risk factor for mortality, cardiovascular disease, and renal disease in general population. However, the relationship between hyperuricemia with clinical outcomes in CKD remains controversial.
Introduction
A large number of epidemiologic studies have suggested the independent role of hyperuricemia on increased mortality, cardiovascular disease (CVD), and renal disease in the general population (1) (2) (3) (4) (5) (6) . However, published data on CKD is limited and inconsistent. Hyperuricema is highly prevalent in CKD, which might account for the decreased renal excretion of uric acid when renal function declines and the association of hyperuricemia with various risk factors for CKD, such as hypertension and diabetes mellitus (DM) (1, 7, 8) . In CKD, it is unclear whether uric acid is merely a marker that reflects the integration of comorbidities and renal damage or a true risk-causative factor for clinical outcomes.
Previous epidemiologic studies in predialysis or dialysis patients suggested a J-shaped association between uric acid and mortality (9, 10) , whereas studies in earlier-stage CKD found a linear relationship for all-cause and cardiovascular mortality (11) . In studies regarding uric acid to renal outcome, one study found that hyperuricemia damaged residual renal function in peritoneal dialysis patients (12) ; one study suggested a weak association in CKD subjects (13) , whereas another study repudiated this association (11) . A recent small, randomized control trial showed that allopurinol treatment lowered uric acid level, slowed renal progression, and reduced cardiovascular and hospitalization risk in moderate CKD (14) . These published data were controversial and limited in sample sizes, population difference, data for calcium, phosphate, and proteinuria, and medication use.
We investigated 3303 stages 3-5 patients from a CKD care system in southern Taiwan to answer the question of whether uric acid is an independent risk factor for mortality, cardiovascular events, and renal outcome.
Materials and Methods

Participants and Measurements
Between November 11, 2002 and May 31, 2009 , 3749 patients who joined the Integrated CKD Care Program Kaohsiung for Delaying Dialysis prospective observation study from two affiliated hospitals (Kaohsiung Medical University Hospital and Kaohsiung Municipal Hsiao-Kang Hospital) of Kaohsiung Medical University in southern Taiwan were included and followed until May 31, 2010 . The definition of CKD by National Kidney Foundation Kidney Disease Outcomes Quality Initiative Guidelines was used, and the CKD stage was classified using subjects' baseline estimated GFR (eGFR). Most of the participants were referred from local medical units or other specialists in the two Gout was defined as either use of hypouricemic agents or clinical diagnosis. CVD was defined as clinical diagnosis of heart failure, acute or chronic ischemic heart disease, and cerebrovascular disease. The BMI was calculated by the baseline enrolled measurement using the formula weight in kilograms divided by height in meters (2) . The mean arterial pressure was calculated by the averaged systolic and diastolic blood pressure measured 3 months before and after the enrollment using the formula one-third averaged systolic blood pressure plus two-thirds averaged diastolic blood pressure. The laboratory data 3 months before and after enrollment of the CKD care system were averaged and analyzed.
Quantification of Renal Function and Progression
Kidney function was quantified by using eGFR derived from the simplified Modification of Diet in Renal Disease (MDRD) Study Equation. The equation was eGFR ml/min per 1.73 m 2 =1863serum creatinine 21.154 3age 20.203 30 .742 (if female patient)31.212 (if black patient). The average eGFR slope (ml/min per 1.73 m 2 /y) for each patient was calculated with varying intercept and varying slope without covariates for estimation of the annual change of eGFR.
Outcomes
Four outcomes were accessed: all-cause mortality, cardiovascular events, renal replacement therapy (RRT), and rapid renal progression. Survival status and cause of death were ascertained by review of death certificates using charts or the National Death Index. Cardiovascular events were ascertained by reviewing charts and defined as the hospitalization for acute coronary syndrome (Deyo's modified Charlson score, ICD-9-CM=410.x-412.x), acute cerebrovascular disease (430.x-438.x), congestive heart failure (428.x), and peripheral arterial occlusion disease (443.9, 441.x, 785.4, V43.4, procedure 38.48) and death by aforementioned cause (16) . The RRT was ascertained by review of charts or catastrophic cards and defined as patients reaching kidney failure that demanded the commencement of hemodialysis, peritoneal dialysis, and renal transplantation. The timing for RRT was according to the regulation of Bureau of the National Health Insurance of Taiwan regarding the laboratory data, nutritional status, uremic status, and GFR. The rapid renal progression was defined as the lowest quartile (the eGFR slope,26 ml/min per 1.73 m 2 /y, an integer near the cutoff point between the lowest two quartiles of the eGFR slope).
Statistical Analyses
Summary statistical results of baseline characteristics of all subjects and stratification by quartiles of uric acid are expressed as percentages for categorical data, mean6SD for continuous variables with approximately normal distribution, and median and interquartile range for continuous variables with skewed distribution.
Cox proportional hazards analysis was used to evaluate the relationship between uric acid and all-cause mortality, cardiovascular events, and RRT. Multivariate logistic regression analysis was used to evaluate the relationship between uric acid and rapid renal progression. To maximize statistical power to examine the relationship between uric acid and clinical outcomes, we analyzed continuous variables with hazard ratios (HRs) presented per 1 mg/dl greater uric acid level and categorical variables with HRs presented by stratification of uric acid quartiles. The analysis was performed with and without adjustment for covariates. Covariates were included into these models if their P value was ,0.05 in univariate analysis, and skewed distribution continuous variables were log-transformed to attain normal distribution. The adjusted covariates included age, sex, cardiovascular factors (CVD), mean arterial pressure, BMI, glycated hemoglobin, cholesterol, current smoker, log-transformed CRP, eGFR, proteinuria, albumin, hemoglobin, bicarbonate, calcium, phosphate, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, diuretics, gout, and hypouricemic agent use. All the analysis was performed in all subjects initially and then, a subgroup of subjects stratified by disease (DM, CVD, hypertension, CKD stage, and gout) for the investigation of the effect of these comorbidities. Interactions between subgroups were tested.
Models for the all-cause mortality included subjects who reached RRT and were censored only at death or the end of follow-up. Models for cardiovascular events were censored at the development of aforementioned events, death, or the end of follow-up. Models for RRT were censored at the commencement of RRT, death, or the end of follow-up.
Results
The mean age of our study subjects was 63.5613.5 years, 57.8% were men, and 44.6% had diabetes. The median of eGFR was 22.4 (11.2-36.3) ml/min per 1.73 m 2 . Mean uric acid level was 7.962.0 mg/dl, and 18.1% of study subjects were on hypouricemic therapy at baseline. Subjects in the higher quartile of uric acid were more likely to be younger and have lower eGFR, heavier urine protein, lower serum albumin and hemoglobin levels, and greater serum CRP and phosphate levels ( Table 1) .
Uric Acid and All-Cause Mortality
There were 471 deaths (14.3%) during a median ;2.8-year follow-up period. For all subjects, regardless of inclusion in unadjusted or full-adjusted models, the highest two quartiles increased risks for mortality. The adjusted HR for quartile 4 versus quartile 1 was 1.85 (95% confidence interval [CI]=1.40-2.44, P,0.001), and the adjusted HR for quartile 3 versus quartile 1 was 1.39 (95% CI=1.05-1.84, P,0.05) ( Table  2) . In subgroup analysis, all subgroups were consistently associated with increased risk for all-cause mortality. There was no significant interaction of any subgroups. The adjusted HRs for those patients with and without DM were 1.13 (95% CI=1.07-1.20, P,0.001) and 1.11 (95% CI=1.03-1.19, P=0.009), respectively (P for interaction=0.93). The adjusted HRs for those patients with and without CVD were 1.27 (95% CI=1.13-1.43, P,0.001) and 1.09 (95% CI=1.04-1.15, P,0.001), respectively (P for interaction=0.07). The HRs for those patients with and without hypertension were 1.13 (95% CI=1.06-1.19, P,0.001) and 1.11 (95% CI=1.02-1.22, P=0.02), respectively (P for interaction=0.30). The HRs for those patients with CKD 5 and CKD 3-4 were 1.09 (95% CI=1.02-1.17, P=0.02) and 1.15 (95% CI=1.09-1.22, P,0.001), respectively (P for interaction=0.05). The HRs for those patients with and without gout were 1.09 (95% CI=0.98-1.21, P=0.10) and 1.12 (95% CI=1.07-1.18, P,0.001), respectively (P for interaction=0.81) (Figure 1 ).
Uric Acid and Cardiovascular Events
There were 545 cardiovascular events (16.5%) during a median ;2.8-year follow-up period. For all subjects, regardless of inclusion in unadjusted or full-adjusted models, the highest two quartiles increased risks for CV events. The adjusted HR for quartile 4 versus quartile 1 was 1.42 (95% CI=1.08-1.86, P,0.05), and the adjusted HR for quartile 3 versus quartile 1 was 1.40 (95% CI=1.08-1.82, P,0.05) ( Table 2) .
Uric Acid and RRT
There were 1080 patients (32.7%) commencing RRT during a median ;2.8-year follow-up period. For all subjects, the significant association between uric acid quartiles and RRT was only observed in the unadjusted model, and this finding became insignificant after adjustment. (The unadjusted HR for quartile 4 versus quartile 1 was 1.81 [95% CI=1.52-2.15, P,0.001], the unadjusted HR for quartile 3 versus quartile 1 was 1.44 [95% CI=1.20-1.72, P,0.001], and the unadjusted HR for quartile 2 versus quartile 1 was 1.24 [95% CI=1.03-1.49, P,0.05]) ( Table  2 ). In the subgroup analysis, all subgroups were not associated with increased risk for RRT, except in subjects with and without DM. The adjusted HRs for DM subgroup and non-DM subgroup were 0.95 (95% CI=0.91-1.00, P=0.04) and 1.04 (95% CI=0.99-1.10, P=0.10), respectively. However, the P value for interaction was not significant (P for interaction=0.08) (Figure 2 ).
Uric Acid and Rapid Renal Progression
There were 841 subjects (25.5%) that had rapid renal progression in our study group. For all subjects, similar to the result of RRT, the association between uric acid and rapid renal progression was only significant in the unadjusted model, but it became insignificant after adjustment. 
Discussion
In our study cohort, hyperuricemia is a risk factor for allcause mortality and cardiovascular events in stages 3-5 CKD patients. The significant relationship between hyperuricemia and renal outcome, including RRT and rapid renal progression, was not observed in our subjects.
The first important finding of our study is the identification of hyperuricemia as a risk factor for all-cause mortality in stages 3-5 CKD. Two previous studies investigated the association between uric acid and mortality in CKD subjects (9, 11) . The relationship between mortality and uric acid observed in our study was similar to the relationship reported by the MDRD trial, which including 840 predominantly nondiabetic stages 3-4 CKD patients (11). It was not similar to the J-shaped relationship observed in the work by Suliman et al. (9) (9) might reflect the different mortality relationship for uric acid between CKD and predialysis CKD. The study subjects in the work by Suliman et al. (9) were CKD stage 5 patients starting RRT. Hence, their result might be closer to the results of hemodialysis patients reported in the work by Hsu et al. (10) , which also found a J-shaped association.
The second important finding of our study is that hyperuricemia is a predictor for increasing cardiovascular events in stages 3-5 CKD. Published data about the relationship between uric acid level and cardiovascular outcomes in CKD were limited to only inclusion of stages 3-4 CKD subjects (11, 17) . In a community-based study including 1678 individuals with stages 3-4 CKD, uric acid was only associated with a composite outcome of myocardial infarction, stroke, and all-cause mortality in univariate analysis, but this association became insignificant in multivariate analysis (17) . In the MDRD trial, including young and predominantly nondiabetic stages 3-4 CKD patients, hyperuricemia seemed to be an independent risk factor for cardiovascular mortality (11) . Our study evaluated a population with a wider range of age and renal function and also more DM proportion, supporting the finding of the MDRD trial.
The third important finding of this study is that hyperuricemia is not associated with increased risk for commencing RRT and rapid renal progression in stages 3-5 CKD patients. In epidemiologic studies investigating the general population (18) (19) (20) (21) (22) , individuals with eGFR.60 ml/min per 1.73 m 2 (2, 23, 24) , and young patients (25, 26) , hyperuricemia was connected to the risk of new-onset or deteriorating kidney disease in most (18-25) but not all (26) studies. Despite the increasing evidence of the independent property of uric acid in the progression of kidney disease in general population, the role of uric acid on renal progression in CKD population remains controversial. Earlier studies found that elevation of uric acid is associated with renal progression in immunoglobulin A nephropathy (27, 28) . In one recent study including 227 nondiabetic CKD patients, the association between uric acid and renal progression was significant in an unadjusted model but became insignificant after the adjustment of baseline GFR and proteinuria (13) . In the MDRD trial, hyperuricemia did not increase risk for ESRD (11) . In our study cohort, hyperuricemia was not associated with renal outcome. It is possible that uric acid plays a less important role in established kidney disease (11) . The more advanced renal disease might attenuate the impact of uric acid on renal progression.
The putative toxic mechanisms of hyperuricemia include mediating inflammation (29) (30) (31) , inducing endothelial cell dysfunction (32) (33) (34) , stimulating vascular smooth muscle proliferation (35, 36) , and increasing oxidative stress (37, 38) . Experimental hyperuricemia could result in hypertension (36, 39) , metabolic syndrome (40) , and renal injury (41, 42) . Consistent with the experimental model, hyperuricemia in humans was proven to be associated with hypertension, diabetes, cardiovascular disease, and CKD (1, 6, 29, 43) . As we know, the former three factors are all risk factors for CKD, and the CKD status will, in turn, complicate the disease control. Hence, there is a vicious circle between uric acid, these cardiovascular conditions, and CKD.
This study has several limitations. First, the cardiovascular event rate was underestimated. Some of our study Figure 1 . | Adjusted hazard ratios (HRs) for all-cause mortality per 1 mg/dl greater uric acid level in all subjects stratified by presence or absence of diabetes mellitus (DM), cardiovascular disease (CVD), hypertension (H/T), gout, and CKD stage. Ratios were adjusted for age, sex, CVD, body mass index, mean arterial pressure, glycated hemoglobin, cholesterol, current smoker, log-transformed C-reactive protein, estimated GFR, urine protein, albumin, hemoglobin, bicarbonate, calcium, phosphate, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker diuretics, gout, and hypouricemic agents. CI, confidence interval. Figure 2 . | Adjusted hazard ratios (HRs) for renal replacement therapy per 1 mg/dl greater uric acid level in all subjects stratified by presence or absence of diabetes mellitus (DM), cardiovascular disease (CVD), hypertension (H/T), gout, and CKD stage. Ratios were adjusted for age, sex, CVD, body mass index, mean arterial pressure, glycated hemoglobin, cholesterol, current smoker, log-transformed C-reactive protein, estimated GFR, urine protein, albumin, hemoglobin, bicarbonate, calcium, phosphate, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker diuretics, gout, and hypouricemic agents. CI, confidence interval. subjects received RRT outsides our two hospitals. If the cardiovascular event developed after that time point and was not treated in our two hospitals, it was not included in our analysis. Fortunately, regardless of the underestimation, the event rate was still adequate to provide significant statistical power in all study subjects. Second, although we used the averaged uric acid level 3 months before and after the enrollment, the uric acid level may have varied during the follow-up period. Additionally, the therapeutic policy of hyperuricemia was not unified. Therefore, the effect of uric acid variation over time was ignored. However, the averaged uric acid is more precise than a single value, which was often used in published studies. Additionally, the baseline uric acid allows prognostication based on current status. Third, the follow-up period is relatively short. The average follow-up time is around 2.8 years. Nearly 65% of our study subjects were stages 3-4 CKD patients that did not reach ESRD in the short period. This limitation will confound the interpretation of the association between uric acid and RRT. Fourth, the study cohort is a referral population at high risk for progression, which may limit generalizability to other CKD populations.
Our study has several strong points. First, we provided calcium and phosphate levels, which are data on elements of bone and mineral disorders of CKD subjects. Abnormality of bone and mineral metabolism, with its sequence of hyperparathyroidism and vascular calcification, often develops in the late stages of CKD, and it has been recognized as an important determinant for outcome. Second, we averaged the multiple assessments of baseline laboratory data, which was more precise and reliable. Third, we included a population with a wider range of age, more stages of CKD, and more disease diversity than other studies. We believe that this study is representative of the common clinical outcomes in stages 3-5 CKD patients.
In conclusion, the current study revealed that, during a nearly 3-year follow-up period, hyperuricemia is a risk factor for all-cause mortality and cardiovascular events in stages 3-5 CKD patients; however, it is not a risk factor for the commencement of RRT and rapid renal progression. This finding reminds us that uric acid may be the modifiable risk factor to improve clinical outcomes.
